Alimentary pharmacology & therapeutics · 2025
Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow-Up Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Riggott Christy, Fairbrass Keeley M, Guthrie Elspeth A, Black Christopher J, Selinger Christian P, Ford Alexander C, Gracie David J
Аннотация
BACKGROUND: Poor psychological health affects many patients with inflammatory bowel disease (IBD), but the persistence of these symptoms is unclear.
METHODS: We performed a longitudinal follow-up study of patients whose anxiety and depression trajectories were established by symptom data collected at 3-monthly intervals over the course of 1 year. We collected further anxiety and depression symptom data at yearly intervals over 2 years to determine the persistence of these symptoms in patients with IBD. Disease outcomes (flare/need for glucocorticosteroids, escalation of medical therapy, hospitalisation, or intestinal resection) were recorded to determine the effect of mood trajectories on the natural history of IBD.
RESULTS: Of 770 patients with established anxiety trajectories, 486 (63.1%) provided further anxiety symptom data at 12 months, and 358 (45.5%) at 24 months. Of the 777 patients with established depression trajectories, 491 (63.2%) provided further depression symptom data at 12 months, and 362 (45.6%) at 24 months. Participants with symptoms of anxiety at 24 months were more likely to have a fluctuating, or persistently abnormal or worsening, anxiety trajectory during the first year (p < 0.001 for trend). Participants with symptoms of depression at 24 months were more likely to have a fluctuating, or persistently abnormal or worsening, depression trajectory during the first year (p < 0.001 for trend). Adverse disease outcomes were no more likely according to anxiety or depression trajectories.
DISCUSSION: Poor psychological health persists for a substantial number of patients with IBD. Further work is needed to establish the long-term effect of mood trajectories on disease outcomes.
METHODS: We performed a longitudinal follow-up study of patients whose anxiety and depression trajectories were established by symptom data collected at 3-monthly intervals over the course of 1 year. We collected further anxiety and depression symptom data at yearly intervals over 2 years to determine the persistence of these symptoms in patients with IBD. Disease outcomes (flare/need for glucocorticosteroids, escalation of medical therapy, hospitalisation, or intestinal resection) were recorded to determine the effect of mood trajectories on the natural history of IBD.
RESULTS: Of 770 patients with established anxiety trajectories, 486 (63.1%) provided further anxiety symptom data at 12 months, and 358 (45.5%) at 24 months. Of the 777 patients with established depression trajectories, 491 (63.2%) provided further depression symptom data at 12 months, and 362 (45.6%) at 24 months. Participants with symptoms of anxiety at 24 months were more likely to have a fluctuating, or persistently abnormal or worsening, anxiety trajectory during the first year (p < 0.001 for trend). Participants with symptoms of depression at 24 months were more likely to have a fluctuating, or persistently abnormal or worsening, depression trajectory during the first year (p < 0.001 for trend). Adverse disease outcomes were no more likely according to anxiety or depression trajectories.
DISCUSSION: Poor psychological health persists for a substantial number of patients with IBD. Further work is needed to establish the long-term effect of mood trajectories on disease outcomes.